Dear Editor, Myelofibrosis is a myeloproliferative entity clinically characterized by
progressive anemia, bone marrow fibrosis, and extramedullary hematopoiesis with …

The JAK2 V617F tyrosine kinase mutation is responsible for the development of BCR/ABL-
negative chronic myeloproliferative disorders, including myelofibrosis (MF). 1–4 Kralovics et …

Dear Editor, Chronic kidney disease (CKD) is present in up to 25% of chronic
myeloproliferative neoplasm (MPN) patients [1–4], which is higher than in the general …

Abstract 2812 Since the discovery of the JAK2-V617F mutation, the relative level of the
mutant allele has been widely studied to gain further insights into the biology of …

Dear Editor, Myelofibrosis (MF), either primary (PMF) or secondary to polycythemia vera
(post-PV MF), is associated with a dismal prognosis in terms of overall survival (OS) and …

JAK2V617F, an activation mutant form of tyrosine kinase JAK2, is found in the majority of
patients with myeloproliferative neoplasms (MPNs) including polycythemia vera (PV) …

Screening of JAK2 V617F point mutation becomes more and more important in monitoring of
JAK2 positive MPN following stem cell transplantation. In an attempt to achieve the required …

A patient with myelofibrosis with myeloid metaplasia displaying the V617F mutation of the
JAK2 gene was given an allogeneic stem cell transplantation using a reduced‐intensity …

To the Editor: Myelofibrosis is a Philadelphia-negative chronic myeloproliferative neoplasm
(MPN) characterized by alteration of the JAK–STAT pathway, primarily through activating …

TO THE EDITOR: Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell
disorders characterized by the proliferation of cells of one or more of the myeloid lineages …